Abstract

An eco-friendly quarantine composition has a function of killing phospholipid enveloped viruses, The eco-friendly quarantine composition includes: 10 to 40 wt. % of polyoxyethylene lauryl ether, 0.01 to 10 wt. % of polyoxyethylene 2-ethylhexyl ether, 0.01 to 10 wt. % of polyoxyethylene polyoxypropylene alkyl ether, and a balance of solvent, based on the total 100 wt. % of the composition. The eco-friendly quarantine composition may have 100% of SARS-CoV-2 virus removal rate in 1 minute and an effect of killing 100% of highly pathogenic avian influenza virus in 1 to 10 minutes. The composition has low cytotoxicity such that IC50 value (%) for human epithelial keratinocyte cells (HaCaT), human bronchial epithelial cells (BEAS-2B), and human monocyte cells (THP-1) is in a range of 0.003 to 0.0045, and effects of having antibacterial activity against non-pathogenic strains, and pathogenic strains.

IPC Classes  ?

• A01N 31/02 - Acyclic compounds
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof

Abstract

This disclosure provides compounds of Formula (I) This disclosure provides compounds of Formula (I) This disclosure provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections.

IPC Classes  ?

• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61P 31/14 - Antivirals for RNA viruses
• C07D 307/93 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Abstract

The present application relates to: a novel isosorbide-based diepoxide compound, a salt thereof, a solvate thereof, and a solvate of the salt thereof; a composition comprising same; use thereof; and a method for preparing same. The novel isosorbide-based diepoxide compound of the present application can be used as a monomer for manufacturing bioplastics, and thus is highly applicable as an eco-friendly material. In addition, the preparation method of the present application enables the synthesis of isosorbide-based diepoxide compounds with high efficiency, and thus can be provided as a useful method for providing isosorbide monomers for manufacturing bioplastics.

IPC Classes  ?

• C07D 493/04 - Ortho-condensed systems

Abstract

An aspect of the present invention is to provide a fluorine-based polymer showing a significantly low dielectric constant of less than 1.8 and a fluorine-based polymer composition including the same. The fluorine-based polymer provided in an aspect of the present invention shows a very low dielectric constant, wherein the polymer is not only a pollution-reducing material generating no harmful substance, but may also be utilized as a coating material in various fields due to high adhesiveness. Furthermore, a polymer film employing the polymer as a material has a volume resistance of about 5.8×1015 Ohmcm, showing an excellent resistance value as an insulating material.

IPC Classes  ?

• C08F 220/14 - Methyl esters
• C08F 220/22 - Esters containing halogen
• C08J 5/18 - Manufacture of films or sheets

Abstract

The present invention relates to a microfluidic device capable of simulating tissues or organs using cells.

IPC Classes  ?

• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12M 1/32 - Inoculator or sampler multiple field or continuous type
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present invention relates to a catalyst for dehydrogenation of glycerol and to a catalyst for dehydrogenation of glycerol, which includes a group 10 element on the periodic table as a catalytically active component and a composite metal oxide composed of zirconium (Zr) and cerium (Ce) as a catalyst support, and a manufacturing method thereof.

IPC Classes  ?

• B01J 23/10 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of rare earths
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/04 - Mixing
• B01J 37/08 - Heat treatment
• C07C 51/295 - Preparation of carboxylic acids or their salts, halides, or anhydrides by oxidation with inorganic bases, e.g. by alkali fusion
• C07C 59/08 - Lactic acid

Abstract

The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Abstract

The present invention relates to a catalyst for producing a synthesis gas by a reforming reaction of a reducing gas using carbon dioxide, and more specifically to a catalyst for producing a synthesis gas, by which, when a composite catalyst comprising nickel-cobalt, used for reforming reducing gas using carbon dioxide, is newly configured and used in a reforming reaction, excellent catalytic activity and stability are achieved, and an excellent conversion rate of a carbon-based reducing gas is gained.

IPC Classes  ?

• B01J 23/89 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with noble metals
• B01J 23/83 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with rare earths or actinides
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst
• C01B 32/40 - Carbon monoxide

Abstract

The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Abstract

The present invention relates to a catalyst support for synthesis gas production, and a catalyst using same. More specifically, a catalyst support used for supporting an active component in a catalyst that is used in synthesis gas production using a reforming reaction in which various reducing agents are used has specific physical properties. Therefore, the present invention relates to a catalyst support and a catalyst prepared using same, the catalyst support being developed such that, if a specific active component of a catalyst is immersed therein and the catalyst is applied to synthesis gas production using a reforming reaction, an excellent catalytic activity effect can be exhibited.

IPC Classes  ?

• B01J 35/30 - Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
• B01J 35/31 - Density
• B01J 35/61 - Surface area
• B01J 35/50 - Catalysts, in general, characterised by their form or physical properties characterised by their shape or configuration
• B01J 23/755 - Nickel
• B01J 23/75 - Cobalt
• C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst
• C01B 32/40 - Carbon monoxide

Abstract

scn1labscn1labscn1labscn1lab gene mutation, of the present invention, exhibits characteristics such as seizure-like behavior, color preference, electroencephalogram characteristics, abnormal expression of specific transcripts, neurotransmitter imbalance and the like, and thus can be effectively used for screening for drugs for treatment of seizure-associated diseases such as epilepsy.

IPC Classes  ?

• A01K 67/0278 - Knock-in vertebrates, e.g. humanised vertebrates
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/22 - Ribonucleases
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a porous support used for the impregnation of a solid polymer electrolyte, a secondary battery comprising same, and a manufacturing method therefor. More specifically, the present invention relates to a porous support used for the impregnation of a solid polymer electrolyte, a secondary battery comprising same, and a manufacturing method therefor, the porous support being capable of utilizing a roll-to-roll process to which in-situ crosslinking is applied.

IPC Classes  ?

• C08J 9/42 - Impregnation with macromolecular compounds
• C08J 9/36 - After-treatment
• C08J 5/22 - Films, membranes or diaphragms
• H01M 10/0565 - Polymeric materials, e.g. gel-type or solid-type
• H01M 10/052 - Li-accumulators
• H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy

Abstract

The present invention relates to a biomarker composition for evaluating drug toxicity of liver organoids, a kit for evaluating drug toxicity of liver organoids, and a method for evaluating drug toxicity of liver organoids. The use of amino acids, which are low molecular metabolites capable of securing measurement reliability, as an index material, allow for the intuitive and reliable measurement for evaluating toxicity of liver organoids, and the measurement of the amino acids in a culture medium, rather than the liver organoid cells themselves, makes it easy to secure a sample and possible to track and observe continuous cell changes. According to the present invention, it is possible to evaluate whether drug-induced liver injury is expressed or not, and not only measurement values of four kinds of amino acid residues, but also ratios between the amino acids can be utilized, so that various approaches can be made according to an applicable measurement method, and the present invention can be utilized even when perfect correction (normalization) such as actual sample usage is impossible.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to: a fluorene-based polymer included in a hole transport layer of a quantum dot light-emitting diode (QD-LED); and a QD-LED comprising same. As fluorine is introduced into the fluorene-based polymer, a HOMO energy level of the hole transport layer is lowered. Therefore, when the fluorine-introduced fluorene-based polymer is included in the hole transport layer, hole injection into an emission layer is improved, and thus performance of the QD-LED may be improved.

IPC Classes  ?

• C08G 61/12 - Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule
• H10K 50/15 - Hole transporting layers
• H10K 50/115 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers comprising active inorganic nanostructures, e.g. luminescent quantum dots

Abstract

According to the present disclosure, by forming normal pressure conditions in a reaction system through application of a reflux system to an aqueous phase in the presence of sulfuric acid and an inorganic salt in the dehydration reaction of biomass-derived sugar components in an open system, there is no need to include a high-pressure vessel required in a conventional 5-halomethylfurfural production process, there is no risk of safety accidents, including the explosion of a high-pressure vessel and the leakage of strong acid gas, and there is a remarkable effect in that yield is improved three-fold or more compared to the case of using a conventionally used acid catalyst under the normal pressure conditions.

IPC Classes  ?

• C07D 307/48 - Furfural

Abstract

The present invention pertains to: an ethylene oligomerization catalyst containing a ligand compound; a catalyst composition employing same; and a method for producing an ethylene oligomer by using same. The catalyst exhibits excellent selectivity to oligomers and selectivity to 1-hexane, thus making it possible to mass-produce 1-hexane, which is an industrially useful chemical raw material, with high purity.

IPC Classes  ?

• C08F 4/78 - MetalsMetal hydridesMetallo-organic compoundsUse thereof as catalyst precursors selected from metals not provided for in group selected from refractory metals selected from chromium, molybdenum, or tungsten
• C08F 110/02 - Ethene

Abstract

The present invention relates to a PBRM1 gene marker for predicting the efficacy of an immune checkpoint inhibitor and use thereof. The E27 selective splicing of a PBRM1 gene, of the present invention, is inversely correlated with the expression level of a RBFOX2 protein, and cancer patients including E27 in the PBRM1 gene have low efficacy of an immune checkpoint inhibitor, while cancer patients excluding E27 have enhanced efficacy of an immune checkpoint inhibitor, thus increasing the survival rate when the immune checkpoint inhibitor is prescribed. Therefore, it is expected that the PBRM1 gene marker can be effectively used in predicting the efficacy of an immune checkpoint inhibitor.

IPC Classes  ?

• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to a cell scaffold for producing cultured meat, a production method therefor, and a method for producing cultured meat using same. More specifically, the present invention relates to a cell scaffold for producing cultured meat, a production method therefor, and a method for producing cultured meat using same, wherein the cell scaffold is capable of adjusting the contents of muscle tissues and adipose tissues at a desired ratio by reversible physicochemical bonding using a self-healing hydrogel capable of self-healing at a temperature and in a pH range at which cells can be cultured.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A23L 13/00 - Meat productsMeat mealPreparation or treatment thereof
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means

Abstract

The present invention relates to a method for recycling mixed polymers comprising a polymer having an urethane functional group and/or a polymer having an amide functional group, in which, in recycling mixed polymers comprising a polymer having an urethane functional group and/or a polymer having an amide functional group, by sequentially or simultaneously bringing, into contact with the mixed polymers, a first compound including at least one aromatic compound having one or more alkoxy functional groups and a second compound including at least one compound having one or more alcohol functional groups, the polymer having an urethane functional group in a composite polymer is selectively dissolved, filtered, and separated, and thus the separated polymer having an urethane functional group can be separately depolymerized.

IPC Classes  ?

• C08J 11/08 - Recovery or working-up of waste materials of polymers without chemical reactions using selective solvents for polymer components
• C08J 11/24 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds containing hydroxyl groups
• C08J 11/28 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic compounds containing nitrogen, sulfur or phosphorus
• C08J 11/16 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with inorganic material
• C08J 11/18 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material

Abstract

The present disclosure relates to an isobenzofuran-1(3H)-one derivative, which is a kinase inhibitor, and a use thereof and, more specifically, to an isobenzofuran-1(3H)-one derivative having HPK1 inhibitory activity and MLK3 inhibitory activity and a pharmaceutical composition containing same for preventing or treating cancer, virus infectious diseases, Parkinson’s disease, non-alcoholic steatohepatitis, or tuberculosis. In addition, the compound can be advantageously used as a composition for prevention or treatment of cancer as it is administered in combination with an anticancer agent or a cell therapy product.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 25/16 - Anti-Parkinson drugs
• A61P 31/06 - Antibacterial agents for tuberculosis
• A61P 31/12 - Antivirals
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

22222 hydrocarbon compounds and aromatic compounds, and an improvement in catalyst regeneration efficiency can be attained, leading to improved economic efficiency.

IPC Classes  ?

• C07C 2/58 - Catalytic processes
• C07C 2/76 - Preparation of hydrocarbons from hydrocarbons containing a smaller number of carbon atoms by condensation of hydrocarbons with partial elimination of hydrogen
• C07C 9/06 - Ethane
• C07C 11/04 - Ethene
• C07C 11/24 - Acetylene
• C07C 15/04 - Benzene
• C07C 15/06 - Toluene
• C07C 15/24 - Polycyclic condensed hydrocarbons containing two rings

Abstract

The present invention relates to a oxygen-free direct conversion of methane reactor and a method for producing ethylene using the same. More specifically, the invention provides a oxygen-free direct conversion of methane reactor and a method for producing ethylene from methane, wherein the reactor is selectively heated to save energy, prevent overheating with high responsiveness, and minimize coke formation, thereby achieving high methane conversion rate and high ethylene yield at a high reaction rate. The method also allows for the production of ethylene and aromatic compounds.

IPC Classes  ?

• B01J 19/24 - Stationary reactors without moving elements inside
• B01J 23/44 - Palladium
• B01J 23/50 - Silver
• B01J 31/28 - Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups of the platinum group metals, iron group metals or copper
• C07C 2/76 - Preparation of hydrocarbons from hydrocarbons containing a smaller number of carbon atoms by condensation of hydrocarbons with partial elimination of hydrogen

Abstract

The present invention relates to: a recombinant polypeptide comprising a bromodomain variant; a chimeric antigen receptor comprising the bromodomain variant in an intracellular signaling domain; a gene construct comprising a nucleotide sequence encoding the recombinant polypeptide or the chimeric antigen receptor; a cell or an immune cell, each expressing the recombinant polypeptide or the chimeric antigen receptor; a pharmaceutical composition for the prevention or treatment of cancer, comprising the immune cell; a composition for degrading the recombinant polypeptide or chimeric antigen receptor of the immune cell, the composition comprising a PROTAC compound as an active ingredient; and a kit for the prevention or treatment of cancer, comprising the pharmaceutical composition and the PROTAC compound.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 9/10 - Transferases (2.)
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed are a plasmid comprising dxCas9 and a CRP derivative for controlling the expression of a target gene, a recombinant strain transformed with the plasmid, a preparation method therefor, a target gene control system, and a method for controlling the expression of a target gene, wherein the plasmid, recombinant strain, and expression control system according to the present invention can improve the production of high-value-added substances by construction of a system for simultaneously and multiply controlling the expression of target genes.

IPC Classes  ?

• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 1/20 - BacteriaCulture media therefor
• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Provided is a secondary battery electrode, which includes a highly adhesive electron conductive layer coupled to an electrode assembly, so as to have improved physical and electrochemical performances. One embodiment of the present invention provides a secondary battery electrode, which includes an electrode assembly and a highly adhesive electron conductive layer coupled to the electrode assembly, wherein the highly adhesive electron conductive layer comprises a substrate and a poly (ethylenedioxythiophene): poly (styrenesulfonate) (PEDOT:PSS).

IPC Classes  ?

• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 4/04 - Processes of manufacture in general
• H01M 10/052 - Li-accumulators

Abstract

The present invention relates to a composite coating film, which has transparency, a self-cleaning function, antibacterial properties, and excellent moisture and oxygen barrier properties. The film comprises: a film substrate; and at least two barrier layers consisting of cellulose-based nanofibers and chitin-based nanofibers substituted with guanidine, which are stacked layer by layer on the film substrate. In addition, the film comprises, on the other side thereof, a self-cleaning porous nano-coating layer in which chitin-based nanofibers substituted with guanidine and inorganic particle layers are alternately stacked layer by layer in two or more layers, wherein the coating layer also comprises an essential oil. The composite coating film provides excellent transparency, oxygen and moisture permeability, and antibacterial effects.

IPC Classes  ?

• C08J 7/04 - Coating
• C08J 7/06 - Coating with compositions not containing macromolecular substances
• C08J 7/054 - Forming anti-misting or drip-proofing coatings
• C08J 5/18 - Manufacture of films or sheets
• C08K 3/36 - Silica
• C09D 101/02 - CelluloseModified cellulose
• C09D 105/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• C09D 5/16 - Anti-fouling paintsUnderwater paints
• C09D 7/62 - Additives non-macromolecular inorganic modified by treatment with other compounds
• B65D 65/42 - Applications of coated or impregnated materials

Abstract

The present invention relates to a nonoxidative methane direct converting reactor and a preparation method of ethylene and aromatic compound using the same and, more specifically, to a nonoxidative methane direct converting reactor and a preparation method of ethylene and aromatic compound using the same, wherein the reactor maximizes a catalytic reaction rate, minimizes cokes production, and provides a high conversion rate of methane and a high yield of ethylene and an aromatic compound even at a low hydrogen supply ratio in the production of ethylene and an aromatic compound from methane.

IPC Classes  ?

• B01J 19/02 - Apparatus characterised by being constructed of material selected for its chemically-resistant properties
• B01J 19/24 - Stationary reactors without moving elements inside
• C07C 2/74 - Preparation of hydrocarbons from hydrocarbons containing a smaller number of carbon atoms by addition with simultaneous hydrogenation

Abstract

The present invention relates to a polymer compound, and an organic photodiode and an X-ray detector comprising same, and relates to: a novel polymer compound having excellent visible light and near-infrared absorption capacity, and being capable of effectively reducing dark current of a device when applied to a photoactive layer of an organic photodiode, thereby significantly improving detection efficiency of visible light and near-infrared; and an organic photodiode and an X-ray detector comprising same.

IPC Classes  ?

• C08G 61/12 - Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule
• H10K 85/10 - Organic polymers or oligomers
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment

Abstract

The present invention relates to a silver nano-zinc oxide composite nanostructure for amplifying a fluorescence signal of a gene probe labeled with fluorescence, to a method for manufacturing same, and to a method for detecting a fluorescence signal and, more specifically, to a silver nano-zinc oxide nanowire in which a nanowire is grown on a substrate, silver nanoparticles formed on the nanowire and a gene probe labeled with fluorescence are comprised, and a distance, at which a metal fluorescence signal can be amplified, between the silver nanoparticles formed on the nanowire and fluorescent molecules of the gene probe is maintained so that the fluorescence signal is amplified. The silver nano-zinc oxide nanowire of the present invention has improved detection sensitivity, thereby enabling more accurate diagnosis.

IPC Classes  ?

• C12Q 1/682 - Signal amplification

Abstract

The present invention relates to: a triazole compound having a novel ring structure; a method for preparing same; and a use thereof. The triazole compound having a novel ring structure according to the present invention exhibits an excellent ability to inhibit ASK1 and inhibits the apoptosis of neurons, and thus can be used for preventing or treating ASK1-related diseases including neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and liver diseases.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to a series of novel pyrazolylmethylurea derivatives, and the use thereof for the inhibition of capsid assembly and the prevention or treatment of viral diseases through the inhibition.

IPC Classes  ?

• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 31/20 - Antivirals for DNA viruses
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 231/16 - Halogen atoms or nitro radicals
• C07D 231/56 - BenzopyrazolesHydrogenated benzopyrazoles
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
• C07D 491/056 - Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
• C07D 495/04 - Ortho-condensed systems

Abstract

2222 in an eco-friendly manner through simple and easy manipulation of SOEC operating conditions.

IPC Classes  ?

• C25B 1/23 - Carbon monoxide or syngas
• C25B 13/07 - DiaphragmsSpacing elements characterised by the material based on inorganic materials based on ceramics
• C25B 9/65 - Means for supplying currentElectrode connectionsElectric inter-cell connections
• C25B 9/19 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms
• C25B 11/051 - Electrodes formed of electrocatalysts on a substrate or carrier

Abstract

A polymer electrolyte composition according to the present disclosure has remarkably excellent yellowing resistance and high adhesive strength, and thus an electrochromic device manufactured by comprising same not only has excellent optical and mechanical durability, but also has a large difference in transmittance between a coloration state and a bleaching state. In addition, the electrochromic device is excellent in coloration and bleaching speeds, and thus can be usefully used as a smart window.

IPC Classes  ?

• C08G 18/10 - Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
• C08G 18/62 - Polymers of compounds having carbon-to-carbon double bonds
• C08G 18/32 - Polyhydroxy compoundsPolyaminesHydroxy amines
• C08G 18/76 - Polyisocyanates or polyisothiocyanates cyclic aromatic
• C08K 3/105 - Compounds containing metals of Groups 1 to 3 or of Groups 11 to 13 of the Periodic Table
• C08F 220/12 - Esters of monohydric alcohols or phenols
• C08F 220/06 - Acrylic acidMethacrylic acidMetal salts or ammonium salts thereof
• C08F 220/20 - Esters of polyhydric alcohols or phenols
• G02F 1/1516 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect characterised by the electrochromic material, e.g. by the electrodeposited material comprising organic material
• G02F 1/1523 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect characterised by the electrochromic material, e.g. by the electrodeposited material comprising inorganic material

Abstract

A lithium sulfide preparation method, according to exemplary embodiments, enables the preparation of a lithium salt-containing superabsorbent polymer by reacting a lithium-sulfur-containing compound solution with a superabsorbent polymer having an absorption rate of 50 g/g to 800 g/g. The lithium salt-containing superabsorbent polymer may be sintered to form lithium sulfide. Accordingly, the stability and economic efficiency of a lithium sulfide production process may be improved, and an eco-friendly process enabling the mass production of lithium sulfide at a low cost may be ensured.

IPC Classes  ?

• C01B 17/22 - Alkali metal sulfides or polysulfides
• H01M 10/0562 - Solid materials
• H01M 10/052 - Li-accumulators

Abstract

The present invention relates to: a catalyst for converting diesel and kerosene, which are increasingly underutilized, into basic chemical feedstock; and a method for producing the catalyst. The catalyst comprises: a porous zeolite; and phosphorus (P) supported in inner pores and on the surface of the zeolite, wherein the amount of Lewis acid sites in the phosphorus-supporting zeolite is 20 to 100 μmol/g, and basic chemical feedstock are produced through catalytic cracking of hydrocarbon feedstock having a boiling point of 150 °C to 550 °C.

IPC Classes  ?

• B01J 29/83 - Aluminophosphates [APO compounds]
• C07C 7/148 - Purification, separation or stabilisation of hydrocarbonsUse of additives by treatment giving rise to a chemical modification of at least one compound
• C07C 11/02 - Alkenes
• B01J 29/40 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11
• B01J 29/08 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the faujasite type, e.g. type X or Y
• B01J 29/70 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of types characterised by their specific structure not provided for in groups
• B01J 29/18 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of the mordenite type
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/04 - Mixing
• B01J 37/08 - Heat treatment

Abstract

The present disclosure relates to a method of polymerizing a polymer having an ester functional group, a catalyst for use in the method, and a composition for use in the method. More specifically, proposed is a method of depolymerizing a polymer having an ester functional group by using potassium carbonate (K2CO3) as a depolymerization catalyst and an alcohol and a polar aprotic solvent as solvents. In addition, a composition for depolymerizing a polymer having an ester functional group is proposed.

IPC Classes  ?

• C08J 11/24 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds containing hydroxyl groups
• C08J 11/16 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with inorganic material

Abstract

The present invention provides a composition for promoting NK cell proliferation or improving cell lysis activity of NK cells, comprising, as an active ingredient, feeder cells in which membrane bound interleukin-13 (mbIL-13) or membrane bound interleukin-2 (mbIL-2) is expressed on a cell membrane. The composition of the present invention expresses mbIL-13 or mbIL-2 on the cell membrane of the feeder cells, thereby having excellent effects of promoting the NK cell proliferation and inducing improvement of cell lysis activity of NK cells.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C07K 14/54 - Interleukins [IL]
• A61K 35/13 - Tumour cells, irrespective of tissue of origin
• A61K 38/20 - Interleukins
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a semiconductor device and a semiconductor material, and more specifically, to an organic semiconductor thin film transistor having a vertical structure, a fusion device of an optical semiconductor material, and a method of manufacturing the same, provides a vertical organic transistor including a substrate, a first electrode layer formed on the substrate, a lower charge transport layer formed on the first electrode layer, a photosensitive layer formed on the lower charge transport layer, an upper charge transport layer formed on the photosensitive layer, a second electrode layer including a base electrode formed on the upper charge transport layer, a plurality of pinholes formed in the base electrode and configured to provide a movement path of charges, and a metal oxide layer surrounding a surface of the base electrode and the pinholes, an organic active layer formed on the second electrode layer, and a third electrode layer formed on the organic active layer.

IPC Classes  ?

• H10K 30/82 - Transparent electrodes, e.g. indium tin oxide [ITO] electrodes
• H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers

Abstract

The present invention provides a polyamic acid aqueous solution composition capable of polymerizing polyamic acid in water rather than in an organic solvent, as well as achieving a high imidization rate during low-temperature curing.

IPC Classes  ?

• C08G 69/32 - Polyamides derived from amino carboxylic acids or from polyamines and polycarboxylic acids derived from polyamines and polycarboxylic acids from aromatic diamines and aromatic dicarboxylic acids with both amino and carboxylic groups aromatically bound
• C08G 73/10 - PolyimidesPolyester-imidesPolyamide-imidesPolyamide acids or similar polyimide precursors
• C08J 3/03 - Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media

Abstract

The present invention relates to a solid polymer electrolyte composition containing a cyclic siloxane-based compound, and a solid polymer electrolyte and a secondary battery comprising the same. Provided are: a solid polymer electrolyte precursor which is obtained by mixing a cyclic siloxane-based compound and a polyalkyleneoxide-based compound and adjusting the viscosity thereof, thereby improving impregnation properties and battery characteristics of a solid polymer electrolyte, and which is suitable for in-situ crosslinking polymerization; and the solid polymer electrolyte, which can be applied to a roll-to-roll production process.

IPC Classes  ?

• H01M 10/0565 - Polymeric materials, e.g. gel-type or solid-type
• H01M 10/0585 - Construction or manufacture of accumulators having only flat construction elements, i.e. flat positive electrodes, flat negative electrodes and flat separators
• C08G 65/34 - Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
• C08G 65/48 - Polymers modified by chemical after-treatment
• C08F 283/06 - Macromolecular compounds obtained by polymerising monomers on to polymers provided for in subclass on to polyethers, polyoxymethylenes or polyacetals

Abstract

The present invention relates to a method for producing a liver organoid comprising maturation of a liver organoid derived from human pluripotent stem cells, and a liver organoid produced therefrom. Unlike an existing method for producing a liver organoid, the method for producing a liver organoid according to the present invention comprises the step of separating cells into single cells by treating the cells with enzymes without physically disrupting the cells, and differentiating the cells by using a 3D cell bioreactor without an extracellular matrix (Matrigel). Therefore, a liver organoid is easy to obtain and can be manufactured in a human-specific manner, and is composed of cells constituting major liver tissues and thus has excellent drug metabolism expression and functions, thereby being able to simulate an actual human liver structure and be used for liver disease research or drug safety evaluation. In addition, the liver organoid can be produced without an extracellular matrix, and thus can also be used in clinical research.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention relates to a sample holder assembly capable of gas or vacuum injection and exhaustion. In particular, the present invention relates to the sample holder assembly having a goniometer base coupled to a sample holder fixed to analysis equipment. The present invention provides the sample holder assembly comprising: the sample holder detachably coupled to a goniometer head; the goniometer base mounted on the sample holder; and a sample loop detachably coupled to the upper portion of the goniometer base, wherein the goniometer base includes: an upper base forming a shape that extends downward from the upper end thereof and reaches the lower end thereof; a lower base extending downward from the lower end of the upper base; and a loop mounting hole penetratingly formed along the upper base and the lower base, and the loop mounting hole allows communication with the sample holder and the sample loop.

IPC Classes  ?

• G01N 23/20025 - Sample holders or supports therefor
• G01N 23/20016 - Goniometers

Abstract

The present invention relates to a composition for diagnosing, preventing, or treating cancer, comprising a phenaleno isoquinolinium-based derivative as an active ingredient and, more specifically, to a theragnosis composition capable of simultaneously diagnosing and treating cancer.

IPC Classes  ?

• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

The present invention pertains to: a method for preparing a catalyst for ammonia decomposition using cation-anion double hydrolysis; the catalyst; and a method for producing hydrogen through ammonia decomposition using the catalyst, wherein a catalyst for ammonia decomposition for hydrogen production, in which nickel (Ni) is supported on an aluminum oxide support or an aluminum composite oxide support doped with a promoter metal (M), is prepared using a ONE POT cation-anion double hydrolysis (CADH) method.

IPC Classes  ?

• C01B 3/04 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of inorganic compounds, e.g. ammonia
• B01J 21/04 - Alumina
• B01J 23/755 - Nickel
• B01J 23/889 - Manganese, technetium or rhenium
• B01J 37/03 - PrecipitationCo-precipitation
• B01J 37/04 - Mixing
• B01J 37/06 - Washing
• B01J 37/08 - Heat treatment
• B01J 37/16 - Reducing

Abstract

The present invention relates to a novel group 14 organometallic compound, a preparation method therefor, and a method for manufacturing a thin film containing a group 14 organometal by using same. The Group 14 organometallic compound according to the present invention is very thermally stable and has excellent volatility and high storage stability, and thus is used as precursor so that a high density and high purity thin film containing a group 14 organometal can be manufactured.

IPC Classes  ?

• C07F 7/00 - Compounds containing elements of Groups 4 or 14 of the Periodic Table
• C23C 16/18 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the deposition of metallic material from metallo-organic compounds
• C23C 16/40 - Oxides
• C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber

Abstract

The present invention relates to a novel strontium compound, a method for producing same, and a method for producing a strontium-containing thin film, using same. The strontium compound according to the present invention is thermally very stable and has excellent volatility and high storage stability, and, thus, a high-density and high-purity strontium-containing thin film can be produced using the strontium compound as a precursor.

IPC Classes  ?

• C07F 3/00 - Compounds containing elements of Groups 2 or 12 of the Periodic Table
• C23C 16/18 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the deposition of metallic material from metallo-organic compounds
• C23C 16/40 - Oxides

Abstract

A catalyst for an ammonia decomposition reaction and a hydrogen production method using the catalyst are proposed. The shape of cerium oxide used as a catalyst carrier for the catalyst is controlled, and cesium (Cs) is included in the catalyst as a catalyst enhancer. Thus, the catalyst increases an ammonia conversion rate and has improved long-term stability.

IPC Classes  ?

• B01J 23/10 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of rare earths
• B01J 23/63 - Platinum group metals with rare earths or actinides
• B01J 35/30 - Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
• B01J 35/40 - Catalysts, in general, characterised by their form or physical properties characterised by dimensions, e.g. grain size
• B01J 35/50 - Catalysts, in general, characterised by their form or physical properties characterised by their shape or configuration
• B01J 35/51 - Spheres
• C01B 3/04 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of inorganic compounds, e.g. ammonia

Abstract

The present invention relates to an extractant and an extraction method for removing color-expressing foreign substances from a colored polymer containing an ester functional group and a method for chemically selecting a polymer containing an ester functional group from a colored polymer mixture and, more specifically, to an extractant capable of effectively removing foreign substances, such as a dye and a pigment, from a colored polymer exhibiting a color by the foreign substances and containing an ester functional group, to a method for eluting most of color-expressing foreign substances by contact with a colored polymer containing an ester functional group while the extractant is maintained at a specific temperature range, and to a method of adding the extractant to a colored polymer mixture to selectively elute foreign substances from only a colored polymer containing an ester functional group and then effectively selecting, through color differentiation, a polymer having the foreign substances removed therefrom and containing an ester functional group.

IPC Classes  ?

• C08J 11/08 - Recovery or working-up of waste materials of polymers without chemical reactions using selective solvents for polymer components
• C08J 11/22 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds
• D06L 4/00 - Bleaching fibres, filaments, threads, yarns, fabrics, feathers or made-up fibrous goodsBleaching leather or furs

Abstract

The present disclosure relates to an optical device having a cross-linked layer. The optical device having a crosslinked layer comprises: a first electrode; an electron transport layer formed on the first electrode; a cross-linked layer formed on the electron transport layer; a perovskite layer formed on the cross-linked layer; a hole transport layer formed on the perovskite layer; and a second electrode formed on the hole transport layer, wherein the cross-linked layer is formed by cross-linking of glycidyltrimethylammonium chloride (GTMACl).

IPC Classes  ?

• H10K 30/85 - Layers having high electron mobility, e.g. electron-transporting layers or hole-blocking layers
• H10K 30/10 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising heterojunctions between organic semiconductors and inorganic semiconductors
• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3
• H10K 30/86 - Layers having high hole mobility, e.g. hole-transporting layers or electron-blocking layers
• H10K 30/81 - Electrodes
• H10K 71/40 - Thermal treatment, e.g. annealing in the presence of a solvent vapour
• H10K 39/10 - Organic photovoltaic [PV] modulesArrays of single organic PV cells

Abstract

The disclosure provides 1,3-dioxoindene compounds as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections.

IPC Classes  ?

• C07D 307/77 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present application provides a polyamic acid aqueous solution composition prepared of a polyimide, wherein the composition enables the polymerization of hydrophobic-based monomers into a polyamic acid in water and is improved in transparency, eco-friendliness, storage stability, and the like when cured.

IPC Classes  ?

• C08G 73/10 - PolyimidesPolyester-imidesPolyamide-imidesPolyamide acids or similar polyimide precursors

Abstract

The present invention relates to a pyrimidine-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for preventing or treating cancer, comprising the same as an active ingredient. The pyrimidine-2,4-diamine derivative exhibits a high inhibitory ability against EGFR and HER2 mutations, and thus can be advantageously used in the treatment of cancer in which EGFR and HER2 mutations have occurred. In addition, the pyrimidine-2,4-diamine derivative exhibits a significant synergistic effect when administered in combination, and thus may be advantageously used in combination therapy.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided.

IPC Classes  ?

• C07K 5/117 - Tetrapeptides the first amino acid being heterocyclic, e.g. Pro, His, Trp
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• C07D 207/04 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07K 5/097 - Tripeptides the first amino acid being heterocyclic, e.g. Pro, His, Trp, e.g. thyroliberin, melanostatin
• C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• C07K 5/107 - Tetrapeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr

Abstract

The present disclosure relates to a catalyst for ammonia decomposition, a manufacturing method therefor, and a method for producing hydrogen using the same. More particularly, the present disclosure relates to a catalyst for ammonia decomposition, a manufacturing method therefor, and a method for producing hydrogen using the same, in which by manufacturing a catalyst for decomposition of ammonia using a solvothermal synthesis method to which alcohol is applied, an ammonia conversion rate can be improved due to excellent catalytic activity in an ammonia decomposition reaction, and hydrogen can be efficiently produced from ammonia due to long-term stability even at a high temperature and for long periods of time.

IPC Classes  ?

• B01J 23/63 - Platinum group metals with rare earths or actinides
• B01J 23/10 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of rare earths
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/03 - PrecipitationCo-precipitation
• B01J 37/10 - Heat treatment in the presence of water, e.g. steam
• C01B 3/04 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of inorganic compounds, e.g. ammonia

Abstract

The present invention relates to a method for synthesizing a large amount of a perovskite crystalline precursor with a high yield in the preparation of a perovskite crystalline precursor. The objective of the present invention is to provide a perovskite precursor mass production method for preparing, in a short time without heat treatment, a large amount of a perovskite precursor with a high yield in kilogram units. Another objective of the present invention is to provide a method for mass producing a perovskite precursor having high crystallinity even while a small amount of a toxic solvent is used. The perovskite precursor mass production method according to the present invention can prepare, in a short time without heat treatment, a large amount of a perovskite precursor having high crystallinity with a high yield in kilogram units even while using a small amount of a toxic solvent so as to have high industrially applicability.

IPC Classes  ?

• H10K 71/15 - Deposition of organic active material using liquid deposition, e.g. spin coating characterised by the solvent used
• H10K 30/10 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising heterojunctions between organic semiconductors and inorganic semiconductors
• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3
• H10K 30/50 - Photovoltaic [PV] devices
• H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers

Abstract

A pyrimidine derivative, a method for preparing the pyrimidine derivative, and a pharmaceutical composition comprising the pyrimidine derivative are disclosed. Also disclosed is a method for preventing or treating cancer which includes administering the pyrimidine derivative or a composition containing the pyrimidine derivative to a subject in need of cancer treatment or prevention. The pyrimidine derivative exhibits a high inhibitory ability against EGFR mutation and HER2 mutation, and thus can be effectively used in treatment of cancer in which EGFR mutation and HER2 mutation have occurred

IPC Classes  ?

• C07D 239/48 - Two nitrogen atoms
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

According to the present specification, disclosed is an experimental device for inhalation exposure to fruit flies and a fruit fly inhalation exposure system comprising same. The present invention can perform various inhalation exposure experiments without material leakage or fruit fly leakage because the device includes a mesh portion and the system utilizes a plurality of devices. Therefore, the present invention can enable toxicity and efficacy experiments for various substances.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• B01L 5/00 - Gas handling apparatus

Abstract

The present disclosure relates to an optical device including a surface-treated perovskite layer. This optical device including a surface-treated perovskite layer includes a first electrode, a first charge transport layer formed on the first electrode, a perovskite layer formed on the first charge transport layer, a second charge transport layer formed on the perovskite layer, and a second electrode formed on the second charge transport layer, wherein the surface of the perovskite layer is surface-treated with phosphonic acids.

IPC Classes  ?

• H10K 30/10 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising heterojunctions between organic semiconductors and inorganic semiconductors
• H10K 30/85 - Layers having high electron mobility, e.g. electron-transporting layers or hole-blocking layers
• H10K 30/81 - Electrodes
• H10K 30/86 - Layers having high hole mobility, e.g. hole-transporting layers or electron-blocking layers
• H10K 30/30 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising bulk heterojunctions, e.g. interpenetrating networks of donor and acceptor material domains
• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3

Abstract

The present invention relates to: a perovskite production method for forming a uniform and dense perovskite thin film even when producing a perovskite thin film having a large area; and an optoelectronic device manufactured using the method. A perovskite crystalline precursor production method, according to the present invention, uses an environmentally friendly solvent and thus enables producing a perovskite precursor having high crystallinity while having high industrial applicability. A perovskite optoelectronic device, according to the present invention, by including a perovskite thin film production method according to the present invention, comprises a uniform and dense perovskite thin film and may have high photoelectric conversion efficiency and photostability.

IPC Classes  ?

• H10K 30/15 - Sensitised wide-bandgap semiconductor devices, e.g. dye-sensitised TiO2
• H10K 71/40 - Thermal treatment, e.g. annealing in the presence of a solvent vapour
• H10K 30/81 - Electrodes
• H10K 30/50 - Photovoltaic [PV] devices
• C01G 21/16 - Halides
• H01L 31/032 - Inorganic materials including, apart from doping materials or other impurities, only compounds not provided for in groups
• H01L 31/075 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof adapted as photovoltaic [PV] conversion devices characterised by at least one potential-jump barrier or surface barrier the potential barriers being only of the PIN type, e.g. amorphous silicon PIN solar cells

Abstract

The novel low-molecular-weight compound according to the present invention has a superior ability to bind to cereblon and thus can act as a novel immunomodulator for treating tumors or cancers.

IPC Classes  ?

• C07D 211/88 - Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
• A61K 31/45 - Non-condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A novel small molecule compound according to the present invention exhibits a very excellent cereblon-binding ability, and thus can act as a novel immunomodulator for treating tumors or cancer diseases.

IPC Classes  ?

• C07D 211/88 - Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
• A61K 31/45 - Non-condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention successively performs hydrodeoxygenation (HDO) and dehydration so that, unlike that of a conventional technique, an alpha-olefin is prepared to have high selectivity, and not an olefin having a double bond at sites other than the alpha position. In addition, according to the present invention, selectivity for alpha-olefin can be further improved under optimal reaction conditions, and an alpha-olefin can be stably prepared with an extended preparation time of up to 180 hours.

IPC Classes  ?

• C07C 1/24 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from organic compounds containing only oxygen atoms as hetero atoms by elimination of water

Abstract

Provided are a copolymer-titanium composite which is crosslinked without a crosslinking agent and an initiator and a copolymer-titanium composite composition including the composite. An organic-inorganic hybrid film produced by including the composition may have a significant refractive index without a large increase in a thickness change rate and may solve a problem of a decrease in optical properties by low dispersibility of a conventional organic-inorganic film by a chemically bonded oxygen-titanium network structure, and an organic film having an excellent refractive index may be provided only with the copolymer.

IPC Classes  ?

• C08F 220/58 - Amides containing oxygen in addition to the carbonamido oxygen
• C08F 8/42 - Introducing metal atoms or metal-containing groups
• C08F 220/30 - Esters containing oxygen in addition to the carboxy oxygen containing aromatic rings in the alcohol moiety
• C08J 5/18 - Manufacture of films or sheets

Abstract

The present invention relates to a fluorine-based polymer coating film, an optical substrate comprising same, and a method for manufacturing the optical substrate, and provides a fluorine-based polymer coating film which is formed from fluorine-based polymer nanoparticles coming in contact and being bound to each other, and which is coated on a substrate to improve infrared transmittance. The fluorine-based polymer coating film according to the present invention has improved infrared transmittance, and since the size of the fluorine-based polymer nanoparticles is controlled to control the ultraviolet-infrared transmittance, transmission wavelength selectivity can be improved.

IPC Classes  ?

• C09D 127/16 - Homopolymers or copolymers of vinylidene fluoride
• C08J 5/18 - Manufacture of films or sheets
• C09D 7/63 - Additives non-macromolecular organic

Abstract

The present invention relates to a nanowire-based immunofluorescence kit for detecting a SARS coronavirus 2 antibody, and a use thereof, and more specifically, to a zinc oxide nanowire-based immunofluorescence kit for detecting a SARS coronavirus 2 antibody, and a use thereof, the kit comprising a step of growing nanowires on a substrate, introducing a functional group on the grown nanowires, and fixing a SARS coronavirus 2 antigen. The nanowire array of the present invention has enhanced detection sensitivity to enable more accurate diagnosis of whether or not a SARS coronavirus 2 antibody is produced.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/531 - Production of immunochemical test materials
• G01N 33/553 - Metal or metal coated

Abstract

The present invention relates to: a method for manufacturing a large-area perovskite forming a uniform and dense perovskite thin film even when manufacturing a large-area perovskite thin film; and an optoelectronic device manufactured using the method.

IPC Classes  ?

• H10K 71/15 - Deposition of organic active material using liquid deposition, e.g. spin coating characterised by the solvent used
• H10K 30/15 - Sensitised wide-bandgap semiconductor devices, e.g. dye-sensitised TiO2
• H10K 71/40 - Thermal treatment, e.g. annealing in the presence of a solvent vapour
• H10K 30/81 - Electrodes
• H10K 30/50 - Photovoltaic [PV] devices
• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3

Abstract

A method for producing olefins using a circulating fluidized bed process, includes: supplying a propane-containing hydrocarbon mixture and a dehydrogenation catalyst into a riser, which is a fast fluidization regime, to cause a dehydrogenation reaction; separating, from a propylene mixture, the catalyst which is a product of the dehydrogenation reaction; removing unseparated hydrocarbon compounds remaining in the catalyst separated in the separating; continuously regenerating the catalyst by mixing the catalyst stripped in the removing with a gas containing oxygen; circulating the catalyst regenerated in the continuously regenerating to the supplying and resupplying it into the riser; and preparing propylene by cooling, compressing, and separating the propylene mixture which is a reaction product separated in the separating.

IPC Classes  ?

• C07C 5/32 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by dehydrogenation with formation of free hydrogen
• C07C 7/00 - Purification, separation or stabilisation of hydrocarbonsUse of additives

Abstract

The present invention relates to an organic antimony compound, a method for preparing same, and a method for forming a thin film using same and, more specifically, to an organic antimony compound, a method for preparing same, and a method for forming a thin film using same, wherein the organic antimony compound exhibits thermal stability and facilitates the formation of a high-quality antimony-containing thin film at low temperatures.

IPC Classes  ?

• C07F 9/90 - Antimony compounds
• C23C 16/18 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the deposition of metallic material from metallo-organic compounds
• C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
• C23C 16/40 - Oxides

Abstract

The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Abstract

A method for preparing a quasi-two-dimensional perovskite thin film, according to one embodiment of the present disclosure, comprises the steps of: coating a substrate with a first solution containing a perovskite precursor; conducting a first-anneal on the coated substrate to form a perovskite thin film; surface-treating the perovskite thin film by using a second solution containing 1, 6-hexanediammonium (HDA) ions; and conducting a second-anneal on the surface-treated perovskite thin film to form a quasi-two-dimensional perovskite thin film.

IPC Classes  ?

• H10K 71/40 - Thermal treatment, e.g. annealing in the presence of a solvent vapour
• H10K 71/15 - Deposition of organic active material using liquid deposition, e.g. spin coating characterised by the solvent used
• H10K 30/84 - Layers having high charge carrier mobility
• H10K 30/10 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising heterojunctions between organic semiconductors and inorganic semiconductors
• H10K 71/12 - Deposition of organic active material using liquid deposition, e.g. spin coating

Abstract

The present invention comprises: a substrate; and a composite oxide thin film located on the substrate, wherein the composite oxide thin film contains zinc oxide and silicon oxide, and the composite oxide thin film is formed by alternately stacking zinc oxide layers and silicon oxide layers, the invention providing excellent light transmittance, gas-blocking performance, and antibacterial effects.

IPC Classes  ?

• C23C 16/40 - Oxides
• C23C 28/00 - Coating for obtaining at least two superposed coatings either by methods not provided for in a single one of main groups , or by combinations of methods provided for in subclasses and
• C23C 28/04 - Coating for obtaining at least two superposed coatings either by methods not provided for in a single one of main groups , or by combinations of methods provided for in subclasses and only coatings of inorganic non-metallic material
• C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber

Abstract

222-) is present in the backbone of a repeating unit; and a side chain part containing an amine-group-containing ether group or thioether group linked to at least some carbons derived from the methylene group of the main chain part.

IPC Classes  ?

• C08F 214/18 - Monomers containing fluorine
• C08F 8/34 - Introducing sulfur atoms or sulfur-containing groups
• C08F 8/30 - Introducing nitrogen atoms or nitrogen-containing groups
• C08J 5/18 - Manufacture of films or sheets

Abstract

A zirconium-copolymer composite and a refractive index control film comprising same, of the present disclosure, are formed with a zirconium oxide network structure, enable amounts to be controlled so as to have an excellent refractive index and have a refractive index, which can be controlled without any physical processing, and do not exhibit, in the visible wavelength range, any color and are highly transparent, and thus can be effectively used in a material such as an optical lens, an OLED or a window film, which requires high transparency.

IPC Classes  ?

• C08F 220/54 - Amides
• C08F 220/58 - Amides containing oxygen in addition to the carbonamido oxygen
• C08F 8/42 - Introducing metal atoms or metal-containing groups
• C08L 33/24 - Homopolymers or copolymers of amides or imides
• C08K 3/18 - Oxygen-containing compounds, e.g. metal carbonyls
• C08J 5/18 - Manufacture of films or sheets

Abstract

The present invention relates to a novel pyrimidine derivative and a use thereof. The pyrimidine derivative has excellent MLK3 inhibitory activity and LRRK2 inhibitory activity and thus can be utilized in a pharmaceutical composition for preventing or treating cancers, virus infectious diseases, Parkinson's disease, nonalcoholic fatty liver disease, and tuberculosis.

IPC Classes  ?

• C07D 239/48 - Two nitrogen atoms
• A61P 35/00 - Antineoplastic agents
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07F 9/6512 - Six-membered rings having the nitrogen atoms in positions 1 and 3
• C07F 9/6541 - Five-membered rings condensed with carbocyclic rings or ring systems
• C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
• C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

In the present invention, an antigen exhibiting higher antigenicity by being fused with a human LRRC24 protein-derived transmembrane domain peptide (LRRC24p) has been discovered, and it has also been identified that a neutralizing antibody is more well-formed even in actual animal experiments. It has been identified that, after inoculation with a recombinant antigen, excellent protective immunity is induced in all mice in a post-immunization challenge test in which SFTSV infection occurs. By using the recombinant antigen exhibiting these results, a vaccine for prevention of SFTSV, which exhibits lethal risk, can be developed.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to an indole compound derivative that decomposes IKZF2 and a use thereof. More specifically, a compound of chemical formula 1 provides an agent having a novel mechanism of action against the IKZF2 protein, and thus is useful for the treatment of diseases and disorders related to the IKZF2 protein, and can in particular be effectively used for preventing or treating cancer.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 35/00 - Antineoplastic agents
• C07D 471/04 - Ortho-condensed systems

Abstract

The present invention relates to a pharmaceutical composition for treating or preventing tankyrase-related cancer diseases comprising an aryl-piperidine derivative compound or a pharmaceutically acceptable salt thereof. The pharmaceutical composition inhibits tankyrase (TNKS) enzymatic activity, inhibits β-catenin target gene expression and active β-catenin protein expression, stabilizes AXIN2 protein levels, and exhibits anticancer activity in cancer cell lines, such that the compound can be used as an anticancer agent, and cause a synergistic effect in combination therapy with other anticancer agents.

IPC Classes  ?

• C07D 211/14 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
• A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 491/113 - Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Abstract

A sensor system for detecting the breakthrough of an atmospheric floating gas adsorption filter according to the present invention measures the saturation adsorption capacity of volatile organic compound from an activated carbon fiber filter equipped with a sensor for measuring the adsorption capacity of volatile organic compounds to determine the time of breakthrough, and thus can determine the time of breakthrough of the filter in a simple manner and increase the utilization of the filter in response to filter breakthrough.

IPC Classes  ?

• G01N 15/08 - Investigating permeability, pore volume, or surface area of porous materials
• G01N 27/04 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance
• B01J 20/20 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbonSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising carbon obtained by carbonising processes
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties

Abstract

The present invention relates to a novel pyrimidine derivative, and a composition for preventing or treating neurodegenerative diseases and cancer, comprising same, the pyrimidine derivative having a LRRK2 protein inhibitory activity, and effectively passing through a blood-brain barrier (BBB) so as to be effectively used as a pharmaceutical composition for preventing or treating neurodegenerative diseases and cancer.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• C07D 491/18 - Bridged systems

Abstract

The present disclosure provides a compound of a specific chemical structure binding to MLKL or having an MLKL inhibiting or degrading activity, or pharmaceutically acceptable salts thereof. The present disclosure provides a composition comprising such compound or pharmaceutically acceptable salts thereof. The present disclosure provides the pharmaceutical use of the compound according to the present invention, salts thereof, and a composition comprising same for treating or preventing MLKL-related diseases. The present disclosure also provides a method for treating or preventing MLKL-related diseases, comprising administering to a subject in need of treatment an effective amount of a compound according to the present invention, salts thereof, or a composition comprising same.

IPC Classes  ?

• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

The present invention relates to a method for producing a cartilage model, comprising the step of simultaneously culturing a porous natural polymer support and a cartilage cell; a cartilage model produced by the method; and a method for testing the activity or toxicity of a test substance, comprising the step of treating the cartilage model with the test substance. A mature cartilage or aged cartilage model that can substitute an animal model may be produced using the method for producing the cartilage model according to the present invention, and the effectiveness and safety of the test substance may be accurately verified using the cartilage model thus produced, and thus, the cartilage model may be diversely utilized in the fields of new medicine development, disease research, and artificial organ development.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a fluoro-functionalized biodegradable polymer comprising a lactide-based monomer unit, a lactone-based monomer unit, and a fluoroalcohol-based monomer unit. The fluoro-functionalized biodegradable polymer according to the present invention comprises a fluorine group due to ring-opening polymerization of biodegradable cyclic ester with fluorine-based alcohol, exhibits thermal stability, can obtain low surface energy, and exhibits excellent properties as a moisture barrier when coated on a cellulose-based surface.

IPC Classes  ?

• C08G 63/682 - Polyesters containing atoms other than carbon, hydrogen, and oxygen containing halogens
• C08G 63/85 - Germanium, tin, lead, arsenic, antimony, bismuth, titanium, zirconium, hafnium, vanadium, niobium, tantalum, or compounds thereof
• C09D 167/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones

Abstract

The present invention relates to a catalyst for an ammonia decomposition reaction, a method for preparing same, and a method for producing hydrogen by using same. More specifically, the present invention relates to a method for preparing a catalyst for an ammonia decomposition reaction, which economically and efficiently supports highly active ruthenium on a lanthanum-cerium composite oxide support, thereby preparing a catalyst that exhibits a higher ammonia conversion rate than conventional catalysts for an ammonia decomposition reaction, to a catalyst for an ammonia decomposition reaction prepared by the same method, and a method for producing hydrogen by using the same.

IPC Classes  ?

• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/00 - Processes, in general, for preparing catalystsProcesses, in general, for activation of catalysts
• B01J 37/16 - Reducing
• B01J 23/63 - Platinum group metals with rare earths or actinides
• C01B 3/04 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of inorganic compounds, e.g. ammonia

Abstract

The present invention relates to a benzamide derivative, a method for preparing same, and a pharmaceutical composition for the prevention or treatment of cancer, containing same as an active ingredient. The benzamide derivative according to an aspect of the present invention can be used in the prevention or treatment of cancer by suppressing EGFR mutation, and, when administered in combination with an EGFR antagonist such as cetuximab, exhibits a significantly synergistic effect on anticancer activity, and thus can be effectively used as an anticancer agent.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 487/08 - Bridged systems

Abstract

The present invention relates to a measurement plate for use in an impedance-based, automatic measurement device for fatty liver and liver fibrosis toxicity, capable of automatically analyzing the fatty liver and/or liver fibrosis toxicity of test drugs being screened and simultaneously processing multiple samples in a non-invasive and highly reproducible way by using cell spheroids, the measurement plate comprising a base plate and at least one cell spheroid receiving part extending up and down through the base plate, wherein: the cell spheroid receiving part comprises a cell spheroid fixing part, arranged at an upper portion, and a lower tube, arranged at a lower portion and in communication with the cell spheroid fixing part; the cell spheroid fixing part is a space having the shape of an inverted, truncated cone; the lower tube is a tubular-shaped space having a diameter smaller than the lowermost diameter of the cell spheroid fixing part; and a cell spheroid may be disposed in the cell spheroid fixing part.

IPC Classes  ?

• G01N 27/02 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
• G01N 33/483 - Physical analysis of biological material

Abstract

The present invention relates to: an oxidation filter module for removing carbon monoxide and volatile organic compounds; and an oxidation filter system, which includes the oxidation filter module, for removing carbon monoxide and volatile organic compounds. More specifically, the oxidation filter module for removing volatile organic compounds adsorbs volatile organic compounds and supplies heat energy to desorb the adsorbed volatile organic compounds and remove carbon monoxide and the volatile organic compounds through catalytic reactions, wherein the adsorption, desorption, and catalytic reactions of the volatile organic compounds can be integrally performed within a catalyst-impregnated activated carbon fabric substrate using self-generated heat without external heating or an internal heating member.

IPC Classes  ?

• B01D 39/20 - Other self-supporting filtering material of inorganic material, e.g. asbestos paper or metallic filtering material of non-woven wires
• B01D 53/04 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
• B01D 46/00 - Filters or filtering processes specially modified for separating dispersed particles from gases or vapours

Abstract

The present invention relates to low-temperature depolymerization, using a cosolvent, of a polymer containing a urethane functional group and a method for producing a polyol, and, specifically, to a method in which a compound having two or more alcohol functional groups is added as a depolymerization solvent for the decomposition of a polymer containing a urethane functional group, and an aromatic compound having an alkoxy functional group is added as a cosolvent to form a reaction system for decomposing a polymer containing a urethane functional group, thereby performing rapid depolymerization at a low temperature, and, through a process of physical separation of a reaction product obtained therefrom, obtaining high-quality recycled polyol at high yield.

IPC Classes  ?

• C08J 11/24 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material by treatment with organic oxygen-containing compounds containing hydroxyl groups
• C08J 11/18 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with organic material

Abstract

The present invention relates to a PVDF-based antibacterial composition and a method for producing same. A method for producing a PVDF-based antibacterial composition according to an embodiment of the present invention comprises the steps of: preparing poly(vinylidene fluoride) (PVDF) and poly(vinylidene fluoride) modified by a pyridinium functional group (Pyd-PVDF); and producing a mixture by mixing the PVDF and Pyd-PVDF in a weight ratio of 99:1 to 93:7. The step of producing the mixture involves continuously performing solid-phase mixing and liquid-phase mixing.

IPC Classes  ?

• A01N 25/34 - Shaped forms, e.g. sheets, not provided for in any other group of this main group
• A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof

Abstract

The present invention provides an impedance-based organoid evaluation system comprising an organoid deformation generating unit including a first tube and a plurality of second tubes having a diameter smaller than that of the first tube, connected to one end of the first tube or inserted therein; and an impedance measuring unit connected to the organoid deformation generating unit and including an impedance analyzer for measuring the impedance of the organoid, and evaluating the organoid from the impedance measured by the impedance measuring unit.

IPC Classes  ?

• G01N 27/04 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance
• C12M 1/26 - Inoculator or sampler
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• G01N 33/483 - Physical analysis of biological material

Abstract

A mixture of a phosphine and a halide, or phosphonium halide which is an intermediate product of reaction therebetween, is provided as an anion exchange precursor of perovskite nanoparticles. According to the present invention, the provision of a novel anion exchange precursor of perovskite nanoparticles enables a light-emitting device which has incorporated the perovskite nanoparticles generated by means of anion exchange to have enhanced luminous efficiency, luminous intensity, and device lifetime.

IPC Classes  ?

• C09K 11/66 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing germanium, tin or lead
• H10K 50/115 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers comprising active inorganic nanostructures, e.g. luminescent quantum dots
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
• B82Y 40/00 - Manufacture or treatment of nanostructures

Abstract

The objective of the present invention is to provide a fluorine-based polymer having a low surface energy, a fluorine-based polymer composition comprising same, a fluorine-based polymer membrane comprising same, and a method for manufacturing same. The present invention provides an acrylate-based copolymer, and in particular, the present invention is characterized in that the number of fluorocarbons in the repeating unit is limited to 3 to 5, such that the surface energy of the polymer and the polymer membrane produced therefrom is significantly lowered. In addition, when the polymer of the present invention is coated on glass, etc., the polymer has the effect of remarkably improving light transmittance, and has excellent mechanical strength.

IPC Classes  ?

• C08F 220/22 - Esters containing halogen
• C08F 220/06 - Acrylic acidMethacrylic acidMetal salts or ammonium salts thereof
• C08F 220/18 - Esters of monohydric alcohols or phenols of phenols or of alcohols containing two or more carbon atoms with acrylic or methacrylic acids
• C08F 220/20 - Esters of polyhydric alcohols or phenols
• C08K 5/29 - Compounds containing carbon-to-nitrogen double bonds
• C09D 5/16 - Anti-fouling paintsUnderwater paints
• C09D 133/16 - Homopolymers or copolymers of esters containing halogen atoms

Abstract

The present invention relates to an insulating gas used for electrical insulation or arc extinguishing of an electrical device, and an electrical device for insulating electricity using the same. The insulating gas of the present invention, which may replace SF6 gas, consists of a mixed gas of trifluoromethyl trifluorovinyl ether (CF3OCFCF2) and a carrier gas. The insulating gas of the present invention has the characteristics of a low boiling point, high dielectric strength, low toxicity, and a low global warming potential (GWP=1 or less), and thus may replace SF6, and the low global warming potential with no loss of high insulating capacity and arc extinguishing capability may reduce greenhouse gases.

IPC Classes  ?

• H01B 3/56 - Insulators or insulating bodies characterised by the insulating materialsSelection of materials for their insulating or dielectric properties mainly consisting of organic substances gases
• H01H 33/56 - Gas reservoirs
• H02B 13/055 - Features relating to the gas

Abstract

The present invention relates to an atmospheric pressure pyrolysis reactor for polytetrafluoroethylene and a method for producing tetrafluoroethylene using same. Specifically, the present invention relates to an atmospheric pressure pyrolysis reactor for polytetrafluoroethylene and a method for producing tetrafluoroethylene using same, wherein the atmospheric pressure pyrolysis reactor comprises: a primary PTFE storage tank capable of storing PTFE in powder, particle, or scrap form; a secondary PTFE storage tank, connected to the primary PTFE storage tank to store PTFE supplied from the primary PTFE storage tank and quantitatively supply the PTFE through a mass flow device arranged at the bottom thereof to a pyrolysis reactor connected below; a steam storage tank for storing steam to be supplied into the reactor; a steam heating means for heating the steam supplied to the reactor; and a vertical pyrolysis reactor for receiving steam heated to a temperature of 500°C to 1000°C by the steam heating means and for performing pyrolysis on PTFE in an atmospheric pressure environment of 1 atm to 1.5 atm.

IPC Classes  ?

• C07C 17/395 - SeparationPurificationStabilisationUse of additives by treatment giving rise to a chemical modification of at least one compound
• C07C 21/18 - Acyclic unsaturated compounds containing halogen atoms containing carbon-to-carbon double bonds containing fluorine
• C08J 11/14 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with steam or water

Abstract

The present disclosure relates to a catalyst for ammonia decomposition, a manufacturing method therefor, and a method for producing hydrogen using the same. More particularly, the present disclosure relates to a catalyst for ammonia decomposition, a manufacturing method therefor, and a method for producing hydrogen using the same, in which by manufacturing a catalyst for decomposition of ammonia using a solvothermal synthesis method to which alcohol is applied, an ammonia conversion rate can be improved due to excellent catalytic activity in an ammonia decomposition reaction, and hydrogen can be efficiently produced from ammonia due to long-term stability even at a high temperature and for long periods of time.

IPC Classes  ?

• B01J 23/63 - Platinum group metals with rare earths or actinides
• B01J 23/10 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of rare earths
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/03 - PrecipitationCo-precipitation
• B01J 37/10 - Heat treatment in the presence of water, e.g. steam
• C01B 3/04 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of inorganic compounds, e.g. ammonia

Abstract

The present invention relates to a novel germanium precursor, a preparation method therefor, and a GeTe thin film manufactured employing same. The germanium precursor has improved thermal stability, exhibiting excellent volatility so as to facilitate the application to a gas phase process, thereby having excellent reactivity with a tellurium precursor, and thus can manufacture a high quality GeTe thin film.

IPC Classes  ?

• C23C 16/30 - Deposition of compounds, mixtures or solid solutions, e.g. borides, carbides, nitrides
• C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
• C07F 7/30 - Germanium compounds

Abstract

The present disclosure relates to a method for recovering styrene monomers from waste polystyrene, and more specifically, to a method for recovering styrene monomers from waste polystyrene, in which the waste polystyrene is depolymerized using an eco-friendly solvent and a potassium-containing carbonate depolymerization catalyst to suppress the generation of ethylbenzene, etc. generated as by-products in a styrene monomer recovery step, and thus the styrene monomers can be recovered in high yield.

IPC Classes  ?

• C08J 11/16 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation by treatment with inorganic material
• C07C 4/22 - Preparation of hydrocarbons from hydrocarbons containing a larger number of carbon atoms by depolymerisation to the original monomer, e.g. dicyclopentadiene to cyclopentadiene

Abstract

22, instead of conventional dual-bed systems consisting of silica and alumina supporting RuSn, HDO and dehydration reactions are performed in one step to selectively remove only oxygen without a loss of carbon in the organic compounds, thereby obtaining hydrocarbon compounds including olefins and paraffins.

IPC Classes  ?

• B01J 23/62 - Platinum group metals with gallium, indium, thallium, germanium, tin or lead
• B01J 23/46 - Ruthenium, rhodium, osmium or iridium
• B01J 21/02 - Boron or aluminiumOxides or hydroxides thereof
• B01J 21/06 - Silicon, titanium, zirconium or hafniumOxides or hydroxides thereof
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/04 - Mixing
• B01J 37/08 - Heat treatment
• C07C 2/76 - Preparation of hydrocarbons from hydrocarbons containing a smaller number of carbon atoms by condensation of hydrocarbons with partial elimination of hydrogen
• C07C 11/02 - Alkenes
• C07C 31/125 - Monohydroxylic acyclic alcohols containing five to twenty-two carbon atoms

Abstract

The present invention relates to a catalyst for dry reforming and, more specifically, to a newly-conceptualized catalyst for dry reforming, the catalyst for dry reforming, which produces a synthesis gas in a reducing-gas-based carbon reaction system, being newly formed using an approach that is completely opposite to a conventional approach, so as to significantly inhibit carbon deposition, which is the greatest challenge in a conventional dry reforming technology, thereby having a significantly extended catalyst lifespan.

IPC Classes  ?

• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• B01J 37/02 - Impregnation, coating or precipitation
• B01J 37/08 - Heat treatment
• B01J 23/75 - Cobalt
• B01J 23/755 - Nickel
• C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst

Abstract

An apparatus for controlling the deposition of an organic-inorganic halide perovskite thin film according to an embodiment of the present disclosure comprises: a substrate for the deposition of organic-inorganic halide perovskite; a vacuum chamber where the substrate is held, a source supplying a halide precursor to the vacuum chamber; a first sensor for measuring a first deposition rate at which the halide precursor is deposited at a location other than the substrate; a second sensor for measuring a second deposition rate at which the halide precursor is deposited on the substrate; and a controller for controlling the rates at which the halide precursors are supplied to the vacuum chamber, respectively, wherein the controller determines the effective deposition rate at which the halide precursor is deposited on the substrate, on the basis of the first deposition rate and the second deposition rate.

IPC Classes  ?

• C23C 14/54 - Controlling or regulating the coating process
• C23C 14/06 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the coating material
• C23C 14/24 - Vacuum evaporation
• H10K 30/10 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising heterojunctions between organic semiconductors and inorganic semiconductors

Abstract

Disclosed is a means for facilitating, in a method for separating and individually collecting organic acids and alkali salts from organic acid alkali salts, separation/collection of lactic acids and alkali salts via an economic and eco-friendly diffusion analysis method without adding a complicated process such as electrodialysis or electrolysis. During a process of diffusion dialysis of organic acid salts, gaseous components that can release protons are injected into a collection part so that the electroneutrality in solution can be maintained and protons can be transferred to a feed part, thereby facilitating the collection of organic acids. Also, alkali cations that have moved to the collection part may form alkali salts with the gaseous components and be then collected, and a nonsolvent may be used to lower the solubility of the alkali salts for easy collection.

IPC Classes  ?

• C07C 51/47 - SeparationPurificationStabilisationUse of additives by solid-liquid treatmentSeparationPurificationStabilisationUse of additives by chemisorption
• B01D 61/24 - Dialysis
• C07C 59/08 - Lactic acid